Nora Yang | Director, Portfolio and Project Management, Strategic Operations, Division of Pre-Clinical Innovation
National Institutes of Health

Nora Yang, Director, Portfolio and Project Management, Strategic Operations, Division of Pre-Clinical Innovation, National Institutes of Health

Nora N. Yang is the director of portfolio management and strategic operations in the Division of Pre-Clinical Innovation at NCATS. In this role, she plans, identifies and manages collaboration opportunities and partnerships; develops new business models to improve efficiency and effectiveness of translational sciences; builds portfolio and project management capabilities; and implements best practices for managing public and private partnerships for NCATS and the Therapeutics for Rare and Neglected Diseases (TRND) program. Yang took a leadership role in building and managing the rare and neglected disease drug development portfolio for the TRND program, which has taken four investigational drugs into rare disease patients in seven clinical trials within three years. Yang brought extensive drug development experience from the biotechnology/pharmaceutical industry to NIH. As a program team leader and project manager at Eli Lilly and Company and at Amgen, Inc., she led teams to manage and develop novel therapeutics for metabolic diseases and oncology indications. She also worked with startup companies and venture capital firms to build and evaluate business proposals and raise investment funds. Yang holds a Ph.D. in molecular biology from the Salk Institute for Biological Studies and the University of California, San Diego, and a master’s degree in management from Stanford University’s Graduate School of Business.


World Orphan Drug Congress USA 2018 - Conference Day Two @ 11:15

Maximizing the impact of public investment to accelerate rare disease therapeutic development

  • Private public partnerships with NCATS to bridge translational gaps – funding and technical expertise
  • Establishing platform technologies at TRND to catalyze rare disease therapeutic development
  • Exploring innovative approaches to unblock regulatory bottlenecks

back to speakers